US87650L1035
US87650L1035
Tarsus Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 3.42B EUR | 2.72B EUR | 3.02B EUR | 3.48B EUR |
Enterprise Value | 2.81B EUR | 2.59B EUR | 2.99B EUR | 3.37B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -203.22x | -- | -- | -- |
Price to Sales | 5.65x | 4.49x | 5.64x | 9.34x |
Price to Book | 9.13x | 7.85x | 8.65x | 10.15x |
EV/Revenue | 4.63x | 4.27x | 5.58x | 9.04x |
EV/EBITDA | -60.79x | -- | -- | -- |
Price to FCF (P/FCF) | 50.74x | 48.63x | -- | -- |
EV/FCF | 41.63x | 46.28x | -- | -- |
FCF Yield | 1.97% | 2.06% | -1.05% | -0.03% |